Nonacus

Nonacus is a commercial-stage diagnostics company specializing in liquid biopsy NGS for precision medicine. Its core technology is the GALEAS platform, supported by the proprietary Cell3 Target enrichment system, which enables highly sensitive detection of genetic variants from minimal sample input. The company markets a portfolio of clinically validated panels for bladder cancer, solid tumors, and hereditary cancers, alongside custom panel design tools and sample collection/isolation kits. Positioned at the intersection of clinical diagnostics and research, Nonacus targets the growing demand for non-invasive genomic testing in oncology and genetic disease management.

GALEAS end-to-end liquid biopsy workflow platform and the proprietary Cell3 Target ultra-sensitive enrichment technology for NGS, enabling detection of variants down to 0.1% VAF from low-input samples.

Nonacus competes in the crowded liquid biopsy NGS market against major players like Guardant Health, Exact Sciences, and Roche, as well as other specialized NGS diagnostic companies. Its differentiation lies in its UK focus, end-to-end workflow, ultra-sensitive Cell3 Target technology, and the flexibility of its custom panel design tool for research applications.